Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Breast Cancer Clinical Trial

Official title:

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases: A Multicenter, Single Arm, Open Label, Phase II Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05357417
• Other study ID #: HNCH-MBC08-BM02
• Status: Recruiting
• Phase: Phase 2
• Start date: April 29, 2022
• Est. completion date: May 2024

Study information

• Verified date: April 2022
• Source: Henan Cancer Hospital
• Contact: Min Yan
• Phone: 15713857388
• Email: ym200678[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to investigate the efficacy and safety of utidelone in combination with bevacizumab in the treatment of advanced breast cancer with brain metastases, and thus provides a new systemic treatment strategy for those patients.

Description:

This is a multicenter,open label, phase 2 trial to investigate the efficacy and safety of utidelone in combination with bevacizumab in the treatment of advanced breast cancer with brain metastases. Patients with HER2-negative advanced breast cancer who have received at least one prior anthracycline and one prior taxane or HER2-positive advanced breast cancer who have failed trastuzumab and pyrotinib, and with at least one measurable CNS lesion are eligible for the study.

This study includes 2 cohorts, and the Simon two-stage design are applied, respectively. A total of 48 patients with HER2-negative advanced breast cancer are included in cohort 1, and 52 patients with HER-2 positive patients are enrolled in cohort 2. Patients in both cohorts receive bevacizumab, 15mg/kg, day 1, and utidelone, 30mg/m2 (±10%), day 1-5 every 3-week cycle until disease progression or unmanageable toxicity. The primary endpoint is CNS-ORR according to the RECIST 1.1. The secondary endpoints include CNS-ORR according to RANO criteria, CNS-PFS assessed by investigator, extracranial ORR, extracranial PFS, OS, time to WBRT, quality of life and safety profile according to NCI-CTCAE 5.0.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Aged = 18 years; histologically or cytologically confirmed invasive breast cancer with metastatic disease; patients without pathologically or cytologically confirmed metastatic disease must have physical or radiological proof of metastasis;

2. With measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension by local radiology;

3. Previously treated with at least one anthracycline and one taxane (as neoadjuvant therapy, adjuvant therapy, palliative therapy, or both);

4. Patients in cohort 2 have failed trastuzumab and pyrotinib treatment;

5. Prior unproven treatment progression with utidelone or bevacizumab;

6. ECOG PS of 0-1 and life expectancy exceeding 12 weeks;

7. Normal organ and bone marrow function; normal blood sample within one week before enrollment (as determined by the laboratory's normal values in each center), including WBC = 3.0 x 109/L, ANC = 1.5×109/L, PLT = 100×109/L; normal kidney and liver function within one week before enrollment (as determined by the laboratory's normal values in each center), including TBIL = 1.5 ULN, SGPT/ALT = 2.5 ULN (= 5 ULN in patients with liver metastases), SGOT/AST = 2.5 ULN, Ccr = 60 ml/min;

8. Neurological lesions must be < grade 2 according to NCI CTCAE version 5.0 within four weeks before enrollment;

9. Without major organ dysfunction or heart disease;

10. Those of childbearing potential should use appropriate contraception before and during study period.

Exclusion Criteria:

1. Patients with leptomeningeal metastases who are not adequately treated by dehydration, hormone therapy, or urgently need radiotherapy;

2. Presence of effusions that cannot be controlled by drainage or other treatment (e.g., massive pericardial, thoracic, or abdominal effusions);

3. Patients received WBRT, chemotherapy, major surgery, targeted therapy or immunotherapy within two weeks before enrollment, received endocrine therapy within one week before enrollment, or received nitrosourea or mitomycin based chemotherapy within six weeks before enrollment;

4. Participation in another clinical trial within four weeks before enrollment;

5. History of grade 3 or 4 allergic events to bevacizumab or utidelone;

6. Contraindications to MRI gadolinium-based contrast agents, such as pacemakers, shrapnel or intraocular foreign bodies;

7. Other malignancies within three years, except for cured cervical carcinoma in situ, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma;

8. More than two seizures within four weeks before enrollment;

9. Insufficiently controlled hypertension, or history of hypertensive crisis or hypertensive encephalopathy;

10. CNS hemorrhage of grade 2 or higher within 12 months before enrollment;

11. NYHA class II or severe congestive heart failure, or history of myocardial infarction or unstable angina within six months;

12. History of hemoptysis within six months before enrollment, or evidence of bleeding tendency or significant coagulation dysfunction within one month;

13. Receiving full dose of warfarin or equivalent currently, or using aspirin (325 mg/day) within ten days;

14. Needs for major surgery, open biopsy or with major trauma within 28 days or during the study period;

15. History of abdominal fistula or gastrointestinal perforation within six months;

16. Presence of unhealed wound, active ulcer or untreated fracture;

17. Any other condition inappropriate for this study deemed by the investigator.

Related Conditions & MeSH terms

• Brain Neoplasms
• Breast Cancer
• Breast Neoplasms
• Neoplasm Metastasis

Intervention

Drug:
• utidelone
30mg/m2 (±10%), day 1-5 every 3-week cycle
• Bevacizumab
15mg/kg, day 1

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CNS-ORR according to the RECIST 1.1.	the proportion of patients with the best intracranial response of confirmed complete or partial response according to RECIST 1·1, as assessed by the investigator	up to 2 years
Secondary	CNS-ORR according to RANO criteria	the proportion of patients with the best intracranial response of confirmed complete or partial response according to RANO criteria, as assessed by the investigator	up to 2 years
Secondary	CNS-PFS assessed by investigator	time from the first dose to disease progression or any-cause death	up to 2 years
Secondary	extracranial ORR	proportion of patients with confirmed extracranial complete or partial response per RECIST 1·1	up to 2 years
Secondary	extracranial PFS	time from the first dose to disease progression or any-cause death	up to 2 years
Secondary	OS	time from the first dose of study drug to any-cause death	Estimated up to 3 year